SCHEMBL29611085

SCHEMBL29611085

COc1ccc(CNc2ncnc3c2c(C#N)cn3[C@@H]2O[C@H](C(=O)Nc3ccc4ccc(N5CCC5)nc4c3)[C@H]3OC(C)(C)O[C@H]32)c(OC)c1

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ METTL3 Q86U44 9/20 0.56
▸ PRMT5 O14744 9/20 0.56
▸ WDR77 Q9BQA1 6/20 0.56
▸ FLT3 P36888 2/20 0.56
▸ ADORA3 P0DMS8 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.35
▸ CYP1A2 P05177 2/20 0.35
▸ CYP3A4 P08684 2/20 0.35
▸ CYP2C9 P11712 2/20 0.35
▸ HSD17B10 Q99714 2/20 0.35
▸ CLK4 Q9HAZ1 2/20 0.35
▸ USP2 O75604 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ HIF1A Q16665 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24313862 1.00 METTL3 (0.56) METTL3PRMT5WDR77FLT3ADORA3
SCHEMBL24313564 0.92 METTL3 (0.46) METTL3PRMT5WDR77FLT3ADORA3
SCHEMBL24313566 0.88 PRMT5 (0.58) METTL3PRMT5WDR77FLT3
SCHEMBL24313866 0.84 ADORA3 (0.42) ADORA3ALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL29610994 0.84 ADORA3 (0.42) ADORA3ALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL24313865 0.84 CYP1A2 (0.43) ADORA3ALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL29611151 0.78 PRMT5 (0.45) METTL3PRMT5WDR77FLT3
SCHEMBL24313513 0.78 PRMT5 (0.45) METTL3PRMT5WDR77FLT3
SCHEMBL24313565 0.74 ADORA3 (0.43) ADORA3ALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL24313864 0.74 ADORA3 (0.43) ADORA3ALDH1A1CYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4229067-A1 METTL3 MODULATORS Accent Therapeutics, Inc. (US) 2023-08-23 — — EP disclosed
WO-2022081739-A1 METTL3 MODULATORS ACCENT THERAPEUTICS, INC. (US) 2022-04-21 — — WO disclosed
Send feedback